Common Lupus Gene Variant Boosts Antiviral Defenses at the Cost of Autoimmunity Risk

Why do genetic variants that raise the risk of autoimmune disease remain so common in the human population? Evolutionary logic would seem to argue that harmful versions of genes should slowly disappear, yet many of the inherited risk factors for conditions such as systemic lupus erythematosus have persisted for countless generations. A new study from investigators at Cincinnati Children’s Hospital Medical Center, published on September 11, 2026, in The American Journal of Human Genetics, offers a compelling possible explanation: some genetic variants that predispose people to lupus may simultaneously make the immune system measurably better at fighting viral infections. The research, led by Leah Kottyan, PhD, Matthew Weirauch, PhD, and Stephen Waggoner, PhD, examined a common lupus-associated haplotype linked to the IRF7 gene, a master transcription factor that sits at the very center of the body’s antiviral immune machinery. What the team found suggests that the boundaries between protective immunity and destructive autoimmunity are far blurrier than the simple language of ‘good’ and ‘bad’ gene variants implies.

Systemic lupus erythematosus is a complex autoimmune disease in which the immune system turns against the body’s own tissues, attacking the skin, joints, kidneys, blood cells, and other organs with chronic inflammation. Genetics plays a substantial role in determining who develops lupus, and many of the genetic regions associated with disease risk have been catalogued for years through large-scale association studies. A major challenge, however, has been moving from statistical association to biological mechanism. Knowing that a stretch of DNA correlates with disease risk says little about what the inherited variant actually does inside immune cells, or why it increases susceptibility not just to lupus but frequently to several autoimmune conditions at once. The new study addresses that gap directly by dissecting what one of the most prevalent lupus-risk haplotypes does to the function of IRF7, a gene whose protein product orchestrates the production of type I interferons, the chemical alarm signals that mobilize antiviral defense throughout the body.

IRF7 helps cells respond to viral infection by activating the production of type I interferons, most notably interferon-alpha, or IFN-α. These signaling molecules are essential components of innate immunity, spreading rapidly from infected cells to their neighbors and instructing them to enter a defensive state that makes viral replication far more difficult. But type I interferon signaling has long been strongly implicated in lupus as well. Many patients with lupus carry a chronically elevated interferon activity in their blood, a phenomenon so consistent that researchers refer to it as the ‘interferon signature,’ and therapies designed to block this pathway have already been approved for treating the disease. The Cincinnati Children’s team reasoned that the connection between these two observations, effective antiviral defense on one side and pathological interferon activity on the other, might run through the genetic variation within IRF7 itself.

That reasoning proved correct. The researchers found that the lupus risk haplotype increases IRF7-dependent induction of IFN-α. In practical terms, individuals carrying this common genetic configuration mount a stronger interferon response under the conditions studied, meaning their antiviral alarm system can ring louder and faster when a viral threat is detected. That heightened responsiveness can be a genuine asset in fighting infection. Yet the very same biology can also promote excessive or inappropriate immune activation, tipping the balance of the immune system toward the self-directed inflammation that defines lupus. The study thereby exposes what the authors describe as an important biological tradeoff, in which a single inherited configuration of the immune system confers both an advantage and a vulnerability depending on context.

The evolutionary implications are striking. A more vigorous antiviral immune response may have been enormously beneficial throughout human history, particularly during eras when infectious diseases represented one of the greatest threats to survival. Populations in which individuals responded more forcefully to viral invasion may have withstood epidemics that devastated others. But an immune system that is especially sensitive to viral signals also carries a greater inherent tendency to cross the line from protective immunity into autoimmunity. The new findings therefore suggest that at least some lupus risk variants should not be thought of as ‘defective’ versions of immune genes at all. Instead, they represent versions of the immune system that simply perform differently, offering an advantage in one environment while increasing disease susceptibility in another. This reframing helps explain why such variants remained common: natural selection may have favored them precisely because of the very biology that now contributes to autoimmune disease.

Sam Virolainen, PhD, first author of the study and a graduate of the Immunology Graduate Program at Cincinnati Children’s, said the findings help explain why a genetic variant linked to lupus remained so common and how, biologically, it affects the immune system more broadly. Reflecting on the training that shaped the work, Virolainen noted an appreciation gained during doctoral research in the Kottyan and Weirauch laboratories that many genetic risk factors can contribute to multiple diseases, especially when the immune system is involved. That multiscale perspective, spanning molecular regulation, cellular signaling, and population genetics, is evident throughout the study’s design and interpretation, and it underscores how a variant’s effect can ripple across very different levels of biological organization.

The work also feeds into a larger and still-unresolved question: how inherited genetic risk interacts with viral infection in the development of autoimmunity. For years, researchers have recognized a strong relationship between Epstein-Barr virus, or EBV, and lupus. Nearly everyone is exposed to EBV at some point in their lives, yet only a small fraction of those exposed ever develop lupus. Genetics may help explain why the consequences of the same viral exposure differ so dramatically from one person to the next. The research team’s previous work examined how viral proteins, including those produced by EBV, interact with the human genome at regions associated with autoimmune disease. The new IRF7 study approaches the gene-virus relationship from the opposite direction. Rather than asking how a virus interacts with genetically susceptible cells, the team asked how inherited genetic variation changes the antiviral response itself, and the answer places both processes on converging molecular roads.

‘Together, these studies support a model in which genetic susceptibility and viral exposure are not independent risk factors. They can converge on the same regulatory pathways,’ said Kottyan. In this model, a person’s inherited genome shapes how strongly their immune system reacts to infection, while viral infection in turn activates molecular pathways that are already tuned by that genetic makeup. In some individuals, the interaction of the two may explain how an ordinary antiviral immune response develops into chronic autoimmune inflammation. The lupus-risk IRF7 haplotype amplifies the interferon arm of this convergence, but the principle likely extends to other immune genes and other autoimmune conditions, offering a framework in which genetics and environment are treated as intertwined rather than separate contributors to disease.

The study does not immediately change how lupus is diagnosed or treated, and carrying this genetic haplotype does not mean that someone will develop the disease. Lupus arises from the combined effects of many genetic variants together with environmental exposures and other biological factors, and no single inherited element is decisive on its own. However, the research demonstrates how scientists can move beyond simply identifying genetic risk factors to understanding, at a mechanistic level, how those variants alter immune function. Studies of this kind help build a foundation for future research into what drives disease and why its course differs from person to person. ‘I am hopeful that our work will increase our understanding of not just lupus biology but other diseases with similar genetic and immunologic complexities,’ said Virolainen. Many disease-associated variants have already been identified, but their biological effects remain unclear. By clarifying the molecular pathways involved, the Cincinnati Children’s team and their collaborators, who spanned institutions across 13 U.S. states and territories and six countries, may ultimately help guide therapies that target disease more precisely while preserving the normal antiviral function that those same variants evolved to protect.

Subject of Research: Genetic and immunological mechanisms linking a common IRF7 haplotype to enhanced antiviral defense and increased lupus risk

Article Title: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics

Article References: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lupus, systemic lupus erythematosus, IRF7, interferon-alpha, autoimmunity, antiviral immunity, genetic haplotype, Epstein-Barr virus, transcription factor, immune genetics, Cincinnati Children's, interferon signature